188Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study
- 7 December 2005
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 33 (3), 344-352
- https://doi.org/10.1007/s00259-005-1954-1
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinomaNuclear Medicine Communications, 2004
- Development and biodistribution of 188 Re-SSS lipiodol following injection into the hepatic artery of healthy pigsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An UpdateAnnals of Internal Medicine, 2003
- Intra-arterial radionuclide therapy for liver tumours: effect of selectivity of catheterization and 131I-Lipiodol delivery on tumour uptake and responseNuclear Medicine Communications, 2003
- Estimating the world cancer burden: Globocan 2000International Journal of Cancer, 2001
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- Lipiodol solution of a lipophilic agent, 188Re-TDD, for the treatment of liver cancerNuclear Medicine and Biology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Intraarterial HCC Therapy with I-131-LipiodolCancer Biotherapy & Radiopharmaceuticals, 2000